The company reported $563.9 million in revenues for the quarter, up from $556.2 million for the same period a year ago.
The partners will provide drug discovery services, expertise, and infrastructure in a new AMRI center located in the Buffalo Medical Innovation and Commercialization Hub.
Revenues for the quarter were down around one percent compared to last year. On a constant-currency basis, though, its sales were up 5 percent.
The deal provides PerkinElmer access to Applied BioCode's Barcoded Magnetic Bead technology, including the BioCode MDx 3000 instrument.
The firm also said that currency translation had a negative effect of $53 million last year.
PerkinElmer's liquid and gas chromatography portfolio will be standardized on Waters' Empower Software.
Bioo licensed technology to reduce ligation bias in NGS and has incorporated it into its RNA-seq library prep kit.
Sales for its human health segment increased a fraction of 1 percent, while the environmental health segment climbed 6 percent.
The Suzhou, China-based laboratory will focus on neonatal testing and infectious diseases, with the potential to expand into cancer testing.
The companies last month agreed to a dismissal of their claims and counterclaims with prejudice, meaning they cannot bring further suit based on the claims.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.